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Abstract
Background: The purpose of this study has been to establish the level of RCAS1 – a membrane
protein expressed in various cancer cells and able to induce apoptosis of CTLs and NK cells in
pharyngeal and laryngeal cancer and its clear surgical margin – with respect to clinicopathological
features and to patient's follow up and evaluate its possible role in cancer relapse.
Methods: A total of 122 tissue samples were obtained: 51 samples from laryngeal and pharyngeal
squamous cell carcinoma, 51 samples from the clear surgical margins of these tumors, and 20 tissue
samples derived from the healthy mucous membranes of the upper respiratory tract mucosa of
patients without cancerous tumors. Patients were observed for a total of 4 years following surgical
treatment. The level of RCAS1 expression was assessed by immunohistochemistry and Western
blot.
Results: RCAS1 was identified in all laryngeal and pharyngeal carcinomas and in almost all the clear
surgical margin samples. The level of RCAS1 expression was significantly higher in the cancerous
samples than in the clear surgical margins and was determined to be related to the grade of the
cancer and the presence of lymph node metastases. In cases of cancer relapse, significantly higher
levels of RCAS1 expression were observed in the clear surgical margins.
Conclusion: Selective cytotoxic immune cell suppression concomitant with tumor growth and
associated with RCAS1 expression seems to be an important event connected with cancer relapse.
Background
Head and neck squamous cell carcinoma constitutes the
sixth most common type of cancer in the world [1]. The
five-year survival rate for patients with this disease has not
improved appreciably since the early 1980s, remaining at
approximately 52% [2,3]. A common problem in cases of
head and neck cancer is the recurrence of the disease
either in the location of primary surgical resection
(although the surgical resection margins were histopatho-
logically free of cancer cells) or in another place. The risk
of a local recurrence of the disease is still high, approxi-
mately 10–30% [4].
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Tumor-associated antigen RCAS1 (receptor-binding can-
cer antigen expressed on SiSo cells) is a type-II membrane
protein, expressed in various human cancer cells [5]. It has
also been detected in blood serum in a soluble form
(sRCAS1) that is probably released from the membrane
form as a result of ectodomain shedding [6,7]. The RCAS1
protein acts as a ligand for a putative receptor present on
various human cells, including normal peripheral lym-
phocytes, such as T, B, and NK (natural killer) cells.
RCAS1 inhibits the growth of receptor-expressing cells
both in vitro and in vivo and induces apoptotic cell death
through the activation of caspase 3 and the collapse of
mitochondrial transmembrane potential [8,9]. RCAS1 is
reportedly expressed with high frequency in breast, lung,
laryngeal, pharyngeal, gallbladder, ovarian, uterine, and
bile duct cancer cells as well as in Reed Sternberg cells and
erythroid progenitor cells [8-18].
RCAS1 expression has also reportedly been associated
with the markers of poor prognosis in various types of
cancers, such as the presence of lymph node metastases in
gallbladder cancer [12] and the high grade of tumor cells
in ductal breast and lung cancers [19,10]; it has addition-
ally been associated with the presence of tumor invasion
in vessels and nerves, and with the depth of tumor inva-
sion in gallbladder cancer [12]. Moreover, RCAS1 expres-
sion has been identified as an independent, negative
prognostic factor in both gallbladder and esophageal can-
cers [12,20]. Furthermore, the RCAS1 blood serum level
has been linked with tumor progression in endometrial
cancer [7]. In our recent study, the soluble form of RCAS1
was detected in the blood serum of patients with head and
neck cancers, while an increase in the sRCAS1 level was
connected with cancer relapse [21]. Sonoda et al. has
pointed out that RCAS1 expression may facilitate cancer
cell invasion of connective tissue through the enhance-
ment of tumor invasive potency by inducing stromal tis-
sue remodeling and the evasion of antitumor immune
surveillance [6].
As RCAS1 expression has not been analyzed in pharyngeal
and laryngeal squamous cell carcinomas and their healthy
stroma, yet has been shown to be involved in tumor inva-
sion, we decided that the levels of RCAS1 expression
should be analyzed with respect to the clinicopathological
features and that patients who underwent surgery due to
pharyngeal and laryngeal squamous cell carcinomas
should be followed up for 4 years.
Methods
Clinical material
All patients in this study with head and neck squamous
cell carcinoma, including pharyngeal (comprises the mes-
opharynx and hypopharynx), and laryngeal cancers,
underwent surgery between September 2002 and Novem-
ber 2003 at the Department of Otolaryngology and Head
and Neck Surgery of the Jagiellonian University in Kra-
kow. The patient's informed consent was obtained in each
case. Additionally, approval for the research program was
obtained from the Ethical Committee of the Jagiellonian
University in Krakow: KBET/379/13/2003. Patients were
randomly selected and observed for a total of 4 years fol-
lowing surgical treatment. The observations were com-
pleted on the 15th of December 2007. A total of 122 tissue
samples were obtained: 51 samples from laryngeal and
pharyngeal squamous cell carcinoma, 51 samples from
the clear surgical margins of these tumors, and 20 tissue
samples derived from the healthy mucous membranes of
the upper respiratory tract mucosa of patients without
cancerous lesions (these patients had been operated on
due to nasal septum deviation). The surgically removed
material was evaluated in order to determine the histolog-
ical type and metastases of the lymph nodes using histo-
logical methods in the Pathology Department of the
Jagiellonian University. Directly following the surgical
procedure, the pathologist collected the cancer tissue sam-
ples and their clear surgical margin samples for examina-
tion. From each patient with laryngeal and pharyngeal
cancer, two samples were collected, one derived from the
cancerous tissue and the other from its clear surgical mar-
gin. The clear surgical margin was defined as the 1 cm2
area of tumor-adjacent tissue macroscopically and histo-
logically free of any neoplasmatic texture. The line of sur-
gical resection was also macroscopically and
histologically free of cancerous texture.
The group of patients
The characteristics of the patient groups are demonstrated
in detail in Table 1. In each case, squamous cell carcinoma
was identified. The cases were staged in accordance with
the TNM Classification of Malignant Tumors, 5th edition
(1997). All patients underwent primary surgical treat-
ment, and 28 received radiation therapy following the
operation because of lymph node metastases. The survival
time was defined as the time from the date of surgery to
the final date of observation in this study (the 15th of
December, 2007).
Preparation of tissue extracts and Western blotting
The Western blot analysis was performed in the Depart-
ment of Analytical Biochemistry, ENT Head and Neck Sur-
gery Department, and the Gynecology and Infertility
Department of the Jagiellonian University. Tissue samples
(average dimensions 0.5 × 0.5 × 0.5 cm) were mixed with
Complete proteinase inhibitor cocktail (Roche, Germany)
and homogenized on an ice-bath in a glass-glass Potter-
Elvejhem homogenizer. The resulting suspensions were
mixed with an equal volume of SDS sample lysis buffer
(4% SDS, 20% glycerol, 125 mM Tris-HCl pH 6.8), boiled
in a water bath for 15 minutes, and spun down. The super-BMC Cancer 2009, 9:35 http://www.biomedcentral.com/1471-2407/9/35
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natants were used for further analysis. A detailed descrip-
tion of the tissue preparation and semi-quantitative
assessment of RCAS1 and beta-Actin relative amounts in
examined tissue samples using Western blot technique
was presented in our previous report [16,18].
Western blotting
The total protein content in the obtained supernatants
was measured using a BCA assay kit. Different sample vol-
umes equivalent to 50 μg/4 g of total protein were loaded
on SDS-PAGE tris-tricine gels (Shagger & von Jagow,
1987). Pre-stained broad range molecular mass protein
standard (BioRad, USA) was used in the marker lane. After
electrophoresis gels were electrotransferred on Immobil-
lon-P polyvinylidene difluoride (PVDF) 0.45 μm mem-
brane (Millipore, USA) in a buffer containing 10 mM 3-
(cyclo-hexyloamino)-1-propanesulfonic acid (CAPS).
The obtained membrane blots were blocked by overnight
agitation in bovine serum albumin in TST buffer (0.01 M
Tris-HCl, pH 7.4, 0.9% NaCl, 0.5% Tween-20). The mem-
branes were then agitated in mouse monoclonal anti-
RCAS1 MoAb 22-1-1 IgM-class antibody (Medical and
Biological Laboratories, Japan) in TST buffer. After dis-
carding the solution and 4 cycles of washing in TST buffer,
the membranes were immersed and agitated in bioti-
nylated anti-mouse IgM μ-chain specific antibody in TST
buffer and, after 4 cycles of washing, in ExtraVidin-alka-
line phosphatase conjugate in TST. After washing, the
color of a band was developed using FastRed TR/Naphtol
AS-MX tablet set. All steps of the procedure were per-
formed at room temperature. Finally, using Western blot
method and monoclonal anti-beta-Actine mouse anti-
body, the relative quantity of beta-Actine was estimated as
a control.
Table 1: Clinicopathological variables for patients with laryngeal and pharyngeal cancer.
Clinicopathologic variable No. of patients
Age (years) 55.3 (42–74)
Men 59.6
Women 53.8
Sex
Men 41
Women 10
Lymph node metastasis
Negative 24
Positive 27
Positive lymph node metastasis without extracapsular spread 11
Positive lymph node metastases with extracapsular spread 16
Tumor size
T1 2
T2 22
T3 23
T4 4
Tumor grade
1 1
2 31
3 19
Pharyngeal cancer 21
Laryngeal cancer 23
Cancer of pharynx and larynx 7
Type of surgery
Total laryngectomies 16
Partial laryngectomies 7
Partial pharyngectomies 21
Laryngopharyngectomies 7
Radiation therapy following surgery 28BMC Cancer 2009, 9:35 http://www.biomedcentral.com/1471-2407/9/35
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Computer- aided image analysis
Fluor-S MultiImager (BioRad, USA) was used to scan the
membranes and the computer program QuantityOne
(BioRad, USA) was used to quantify band intensities. All
calculations were performed for the RCAS1 antigen hav-
ing a molecular mass of about 32 kDa [17]. The intensities
of this band were expressed in arbitrary relative units, and
one unit (U) was defined as the band intensity produced
by the reference sample, randomly chosen, yet the same
on all blots, and always applied in the same amount.
Because all immunoblots contained the same RCAS1
quantity standard and all lanes were loaded with the same
amount of total protein (50 μg/4 g), the values deter-
mined were highly repetitive and independent of the con-
ditions of the experiment. The results indicated the
relative amount of RCAS1 32 kDa antigen in 50 μg/4 g of
total sample protein.
Immunohistochemistry
Two independent observers with no knowledge of the
clinicopathologic data reviewed the immunohistochemi-
cal expression of RCAS1. Immunohistochemical analysis
was performed in the Pathomorphology Department of
the Jagiellonian University. 5 μm thick slides were depar-
affinized, rehydrated, and rinsed in distilled water. Endog-
enous peroxidase activity was blocked by 8 minutes of
incubation in 3% H2O2 at room temperature. The slides
were then rinsed and immersed in boiling citrate buffer
(pH 6.0) in a microwave oven with three changes of buffer
for 5 minutes each. For the immunolocalization of RCAS1
the slides were treated with the mouse monoclonal anti-
body Anti-RCAS1 (Medical and Biological Laboratories,
Naka-ku Nagoya, Japan in DAKO Antibody Dilutent with
Background Reducing Components-DAKO, Denmark,
dilution 1:1000) in a moist chamber overnight. The slides
were subsequently rinsed in TBS buffer (pH 7.6) and incu-
bated with secondary antibody (DAKO Envision TM+ Sys-
tem Labelled Polymer HRP – anti-mouse (DAKO,
Denmark) for 30 minutes at room temperature. Visualiza-
tion was performed using AEC (3-amino-9-ethyl-carba-
zole) as a chromogen (AEC Substrate Chromogen ready-
to-use, DAKO, Denmark) for 10 minutes at room temper-
ature. The sections were counterstained with hematoxylin
and mounted in glycergel. We assumed that positive reac-
tivity for RCAS1 occurred when we observed a granular
cytoplasmic (rarely membranous) staining pattern in at
least 10% of cells with the following intensity: 0- no reac-
tivity; 1-weak (10–25% positive cells); 2-moderate (26–
50% positive cells); 3-overexpression (51–100% positive
cells).
Statistical analysis
The distribution of subjects was analyzed using the Sha-
piro-Wilk's test. The resulting data and control data were
compared using Student's t-test (the relative amount of
RCAS1) and the Mann-Whitney test (β-Actin). Signifi-
cance was accepted at p < 0.05.
Results and discussion
The expression of RCAS1 in laryngeal and pharyngeal 
squamous cell carcinoma and clear surgical margin
The Western blot analysis revealed 32 kDa bands corre-
sponding to RCAS1 protein and 42 kDa bands corre-
sponding to beta-Actin, control protein, Figure 1[17,18].
RCAS1 protein was not detected in the tissue samples
derived from the healthy mucous membranes of the
upper respiratory tract of the patients without cancerous
lesions by means of Western blot method.
RCAS1 expression was established in all pharyngeal and
laryngeal squamous cell carcinoma tissue samples. Immu-
nohistochemical analysis confirmed the expression of
RCAS1 in all the cancer tissue specimens. The granular
type of diffused cytoplasmic expression was evaluated
(Figure 2, Figure 3).
The presence of RCAS1 was also revealed in immunohis-
tochemistry in almost all (96.5%) the samples derived
from histopathologically negative surgical margins.
RCAS1 immunoreactivity in stratified squamous epithe-
lium from healthy surgical margin was present mostly in
the superficial layers of the epithelium, while RCAS1
immunoreactivity identified in the stratified columnar
epithelium was present only in the margins of the epithe-
lium as a very intense brown reaction. The immunoreac-
tivity of RCAS1 remained at the highest level in close
vicinity of the cancer and was observed to decrease as the
distance from the tumor increased (Figure 4). The type of
staining pattern in the healthy epithelium was diffused
granular cytoplasmic and/or membranous (Figure 5).
In Western blot technique, RCAS1 was identified as a 32 kDa  band, while beta-actin control protein corresponded to 42  kDa band Figure 1
In Western blot technique, RCAS1 was identified as 
a 32 kDa band, while beta-actin control protein cor-
responded to 42 kDa band. Each column corresponds to 
a tissue sample derived from a cancer nest.BMC Cancer 2009, 9:35 http://www.biomedcentral.com/1471-2407/9/35
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RCAS1 immunoreactivity was statistically significantly
higher in the cancerous tissue specimens than in the clear
surgical margin. The results obtained through immuno-
histochemical analysis remained in compliance with
those obtained by the Western blot method. No differ-
ences were observed in the average relative amount of β-
Actin control protein between examined groups of
patients (Table 2, Table 3).
We also assessed the RCAS1 expression level with respect
to the clinicopathological variables (tumor size, grade,
and the presence of lymph node metastases) using West-
ern blot method. No differences were identified in the rel-
ative amount of RCAS1 with respect to tumor size.
However, the average relative amount of RCAS1 was
found to be statistically significantly higher in the samples
taken from high-grade cancers (Table 4).
The average relative amount of RCAS1 was identified as
significantly higher in patients with lymph node metas-
tases in comparison to patients without lymph node
metastases (Table 5).
The average relative amount of RCAS1 was also statisti-
cally significantly higher in patients with the presence of
lymph node metastases in which the presence of the ext-
racapsular spread of cancer infiltration was observed than
in patients who did not exhibit the extracapsular spread
(Table 6).
RCAS1 immunoreactivity was identified as a granular type of  staining pattern in cancer specimens Figure 2
RCAS1 immunoreactivity was identified as a granu-
lar type of staining pattern in cancer specimens.
RCAS1 expression in cancer nest Figure 3
RCAS1 expression in cancer nest.
RCAS1 immunoreactivity in clear surgical margin decreased  as the distance from the tumor increased Figure 4
RCAS1 immunoreactivity in clear surgical margin 
decreased as the distance from the tumor increased.
RCAS1 expression in clear surgical margin presenting mem- brane staining pattern Figure 5
RCAS1 expression in clear surgical margin present-
ing membrane staining pattern.BMC Cancer 2009, 9:35 http://www.biomedcentral.com/1471-2407/9/35
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RCAS1 expression and the recurrence of the disease
We assessed the expression of RCAS1 in cancer and in
clear surgical margin derived from all examined patients
with respect to the recurrence of the cancer process by
evaluating a group of 19 patients who had suffered a
relapse during the period of observation following surgi-
cal treatment.
Western blot analysis revealed that the level of RCAS1
expression in clear surgical margin was statistically signif-
icantly higher in tissues derived from patients who had
experienced a recurrence of the disease than in patients
who had recovered. Interestingly, no differences between
the two groups of patients with respect to RCAS1 expres-
sion levels in the cancer cells themselves were found using
both biochemical techniques. Additionally, no differ-
ences were observed between the examined groups with
respect to beta-Actin control protein (Table 7).
A strong immunoreactivity level in the clear surgical mar-
gin was observed in one patient who had experienced a
recurrence of the disease 6 months after radical surgical
treatment. Cancer recurrence was also observed in 78% of
patients with a moderate level RCAS1 immunoreactivity
within the clear surgical margin. In the group with a weak
level of RCAS1 reactivity in the clear surgical margin, only
15% of the patients experienced a recurrence. Moreover,
the RCAS1 immunoreactivity level was observed to
decrease as the distance from the tumor increased. In cases
of cancer recurrence, the RCAS1 level ranged from moder-
ate in the tissues adjacent to the tumor to weak in the
resection line. There were no recurrences in patients in
whom the RCAS1 immunoreactivity level ranged from
weak in the tissue adjacent to the tumour to absent in the
resection line (Table 8).
RCAS1 expression was confirmed by Western blot and
immunohistochemical methods in all pharyngeal and
laryngeal squamous cell carcinoma specimens and in
almost all histopathologically clear margins, but was not
detected in the healthy mucous membranes derived from
the upper respiratory tract of the patients without cancer-
ous lesions. RCAS1 expression has been reported in vari-
ous cancers and its expression has been associated with
such markers of poor prognosis as tumor size, the pres-
ence of lymph node metastases, a high grade of tumor
cells, and the depth of tumor invasion [8-18]. RCAS1
expression has been detected in uterine cervical cancer by
Sonoda et al., and it has been proposed that this expres-
sion is related to tissue remodeling. Sonoda et al. has con-
cluded that RCAS1 expression might be responsible for
the depth of tumor invasion [6,19]. Moreover, the study
determined that RCAS1 was significantly associated with
the expression of VEGF and microvessel density. Conse-
quently, it was concluded that RCAS1 might be responsi-
ble for regulating the angiogenesis of the tumor and in
this way might control tumor growth [19].
As in these reports, we found that RCAS1 expression was
associated with high tumor grade and the presence of
Table 2: RCAS1 immunoreactivity in pharyngeal and laryngeal cancer and clear surgical margin derived from the same individuals.
RCAS1 immunoreactivity
Variables Number - +1 +2 +3
Pharyngeal and laryngeal squamous cell carcinoma 51 0 0 22 (44%) 29 (56%)
Clear surgical margin 51 1
(3.5%)
24 (44.5%)* 25 (48.5%)* 1
(3.5%)
*The change in the intensity of immunoreactivity was observed in six specimens (12%), in one case in the group of the +1 RCAS1 immunoreactivity 
and in 5 cases in the group of +2 RCAS1 immunoreactivity; the expression decreased with the distance from cancer cells. In four examined samples, 
the RCAS1 immunoreactivity level in closely tumor-adjacent tissue was established as moderate and decreasing to weak in the line of resection. In 
two cases, weak RCAS1 immunoreactivity in the directly tumor-adjacent tissue diminished to the point of absence in the resection line.
Table 3: The comparison of the average relative amount of RCAS1 as assessed by the Western blot method in carcinoma and cancer-
free surgical margin.
Pharyngeal and laryngeal squamous cell carcinoma (n = 51) Clear surgical margin (n = 51) P
Average RCAS1 relative amount (± SD) 1.1016
(± 0.6090)
0.891
(± 0.5237)
0.02
Average β-Actin relative amount (± SD) 1.21163
(± 0.648)
1.2286
(± 0.47)
NS
RCAS1/β-Actin ratio 0.909 0.725 -
NS-no statistical significance
SD-standard deviationBMC Cancer 2009, 9:35 http://www.biomedcentral.com/1471-2407/9/35
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lymph node metastases, especially with extracapsular
spread. RCAS1 expression in pharyngeal and laryngeal
healthy surgical margin would thus seem to be very signif-
icant. Initially, the RCAS1 staining pattern in all the spec-
imens – both the cancer specimens and their clear surgical
margins – appeared to be the same diffused granular
staining pattern. However, the pattern was always present
in the cytoplasm but was rarely seen on cell membranes.
Furthermore, the RCAS1 content was high in the cancer-
ous cells and its expression decreased as the distance from
the tumor increased (Figure 4).
To our knowledge, this is the first investigation to focus on
RCAS1 stroma expression in pharyngeal and laryngeal
cancer with respect to cancer relapse.
In the present study, a high level of RCAS1 expression in
healthy surgical margin, including healthy stroma, was
associated with a higher frequency of local cancer recur-
rence within the period of observation. The participation
of the stroma in cancer invasion is an intriguing finding.
In our previous report, MT expression was identified in
the healthy tissue adjacent to cancerous tumors of the
head and neck and breast [22]. The tumor environment
has been typified by the MT over-expression that may
result from the destruction of local physiological proc-
esses regulating the stromal invasion [22].
The biological role of RCAS1 involves the inhibition of
activated lymphocytes and the induction of the apoptosis
of activated CTLs and NK cells [8,17,20]. The level of
RCAS1 expression has been found to be inversely related
to the infiltration of CD3 positive lymphocytes of a tumor
in breast cancer [23,24]. Moreover, RCAS1 expression has
been associated with the number of apoptotic lym-
phocytes adjacent to tumor cells in both lung cancer and
Hodgkin's disease [9,24]. An increase in the apoptosis of
lymphocytes (mainly CD3+) has also been observed in
uterine cervical cancer surrounding RCAS1 positive-can-
cer cells and RCAS1-positive metastatic cancer cells in
lymph nodes [6].
Finally, we have recently described the participation of
RCAS1 in the regulation of cytotoxic immune response in:
Waldeyer's ring tissue, nasal polyps, the endometrium,
and the placenta [25-29].
RCAS1 would therefore seem to play an important role in
regulating immune responses. Its expression in the pla-
centa during pregnancy enables the development of the
Table 4: The comparison of the average relative amount of RCAS1 as assessed by the Western blot method in carcinoma and cancer-
free surgical margin in relation to the tumor grade.
Average relative amount of RCAS1 ± SD
Tumor grade G2 (n = 31) G3 (n = 19) P
Pharyngeal and laryngeal squamous cell carcinoma 0.987
(± 0.522)
1.2211
(± 0,6937)
0.04
Clear surgical margin 0.6922
(± 0.4699)
0.996
(± 0.3808)
0.03
SD-standard deviation.
No differences were observed in the average relative amount of β-Actin control protein.
Table 5: The comparison of the average relative amount of RCAS1 as assessed by the Western blot method in laryngeal and 
pharyngeal cancer specimens with respect to the presence of lymph node metastases.
Lymph nodes N negative
(n = 24)
N positive
(n = 27)
P
RCAS1 average relative amount in cancer (± SD) 0.984
(± 0.5883)
1.287
(± 0.5504)
0.04
Average β-Actin relative amount in cancer (± SD) 1.132
(± 0.532)
1.282
(± 0.723)
NS
RCAS1/beta Actin ratio in cancer 0.862 1.003 -
RCAS1 average relative amount in clear surgical margin (± SD) 0.805
(± 0.550)
0.869
(± 0.483)
NS
Average β-Actin relative amount in clear surgical margin (± SD) 1.072
(± 0.473)
1.192
(± 0.386)
NS
RCAS1/beta Actin ratio in clear surgical margin 0.75 0.72 -
SD-standard deviationBMC Cancer 2009, 9:35 http://www.biomedcentral.com/1471-2407/9/35
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maternal immune tolerance. Furthermore, RCAS1
decreases before labor, making the maternal immune tol-
erance phenomenon reversible [29,30]. RCAS1 has also
been found in the epithelium of nasal polyps, as well as in
their microenvironment, where its expression by macro-
phages (CD68 positive cells) has been confirmed. It is
thus involved in the regulation of the local chronic
inflammatory process [25]. Cancer is characterized by two
phenomena related to RCAS1 expression: one is the
chronic perpetual inflammation accompanying cancer;
the other phenomenon is that of the host immune toler-
ance which enables tumor growth. In both situations,
RCAS1 may participate in the chronic inflammatory proc-
ess as an important suppressor of the anti-tumor immune
response as well as in the development of pro-tumor tol-
erance. RCAS1 expression in the tumor has been shown to
increase tumor invasiveness [7-19], but its expression by
the healthy epithelium of adjacent tissues may result from
the increase in local immune deregulation, making the
tolerance irreversible and facilitating tumor invasion in
tumor-tolerant adjacent tissues. This may be why we
observed a recurrence of the disease in the patients with
high levels of RCAS1 expression in the clear surgical mar-
gins while patients who exhibited no RCAS1 expression in
the tumor margins or in the resection line had no relapse.
Like Sonoda et al. in the study [7] on endometrial cancer,
we have demonstrated that in pharyngeal and laryngeal
cancer patients, the sRCAS1 blood serum concentration
level increases as the tumor progresses. Moreover, as was
also observed in the Sonoda et al. study [7], sRCAS1 con-
centration level in head and neck cancer patients has been
found to decrease following surgical treatment but to
increase again if the cancer recurs [30,7]. Furthermore, the
blood serum sRCAS1 concentration level in squamous
cell carcinomas has been shown to be higher in the sec-
ondary cancer than it was in the primary cancer (before
the surgery). A tumor suppresses immune system activity
not only locally, but also generally, and the effect of this
suppression is long term [31]. Most likely the increase of
sRCAS1 blood serum concentration associated with can-
cer relapse indicates that sRCAS1 might suppress the
immune system generally, thus enabling the relapse. The
expression of RCAS1 in clear surgical margin also seems to
be related to the local suppression of cytotoxic immune
cells around the tumor that along with tissue remodeling
may facilitate tumor invasion, thus resulting in cancer
relapse.
Conclusion
In conclusion, the selective cytotoxic immune cell sup-
pression concomitant with tumor growth and connected
with locally occurring RCAS1 expression (stromal RCAS1
expression) seems to be an important event related to can-
cer recurrence.
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Table 6: The comparison of the average relative amount of RCAS1 as assessed by the Western blot in laryngeal and pharyngeal cancer 
specimens obtained from patients with lymph node metastases with and without the presence of extracapsular spread.
Lymph nodes The presence of extracapsular spread
(n = 16)
No extracapsular spread
(n = 11)
P
Average relative amount of RCAS1 in cancer (± SD) 1.4631
(± 0.5285)
0.8681
(± 0.4362)
0.0011
Average β-Actin relative amount in cancer (± SD) 1.034
(± 0.731)
1.102
(± 0.481)
NS
RCAS1/beta Actin ratio in cancer 1.414 0.787 -
RCAS1 average relative amount in clear surgical margin (± SD) 0.859
(± 0.529)
0.831
(± 0.500)
NS
Average β-Actin relative amount in clear surgical margin (± SD) 1.1806
(± 0.477)
1.058
(± 0.472)
NS
RCAS1/beta Actin ratio in clear surgical margin 0.727 0.785 -
SD-standard deviation
Table 7: The comparison of the average relative amount of RCAS1 in laryngeal and pharyngeal squamous cell carcinoma and in its 
clear surgical margin with respect to disease recurrence within one-year follow up.
No Recurrence
(n = 32)
Recurrence
(n = 19)
P
RCAS1 average relative amount in pharyngeal and laryngeal squamous cell carcinoma (± SD) 1.097
(± 0.5505)
1.1067
(± 0.6874)
NS
RCAS1 average relative amount in clear surgical margin (± SD) 0.5504
(± 0.3086)
1.2575
(± 0.4579)
0.0002BMC Cancer 2009, 9:35 http://www.biomedcentral.com/1471-2407/9/35
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